TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15693450
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Study: 15693450
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of triple therapy (omeprazole 20 mg, clarithromycin 250 mg, tinidazole 500 mg)
Study: 15693450
Drug: 1 week
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 week of triple therapy
Study: 15693450
Drug: 2 weeks
Normalized name: Rykindo, 25 mg/2 weeks intramuscular powder for injection, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 weeks of triple therapy
Study: 1901638
Drug: Leuprolide acetate
Normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprolide acetate depot, 3.75 mg intramuscularly every 4 weeks for 24 weeks
Study: 25847559
Drug: 1mg/kg Ginkgo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/kg Ginkgo biloba extract (G group n=30)
Study: 7559260
Drug: Zaditen SRO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zaditen SRO 4 mg once daily
Study: 7559260
Drug: Zaditen SRO
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zaditen SRO 2 mg once daily
Study: 7559260
Drug: Zaditen Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zaditen Standard Form 1 mg twice daily
Study: 2196774
Drug: Intravenous captopril
Normalized name: Captopril
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous captopril (n = 8)
Study: 3653591
Drug: Nifedipine 60
Normalized name: nifedipine 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 60 mg/day
Study: 7025625
Drug: Propranolol 280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 280 mg/day
Study: 1732370
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Nifedipine and Propranolol
Study: 29199100
Drug: Universal antiretroviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Universal antiretroviral therapy (ART) with fixed-dose combination of tenofovir, emtricitabine, and efavirenz, regardless of CD4 cell count.
Study: 24395288
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and cholecalciferol supplementation (1,000 mg/day calcium and 800 IU cholecalciferol)
Study: 29654643
Drug: Sitagliptin 25
Normalized name: SITagliptin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin 25 mg
Study: 17156104
Drug: Sitagliptin (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sitagliptin (all doses)
Study: 2883488
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily)
Study: 30892987
Drug: Encorafenib 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encorafenib 300 mg daily, binimetinib 45 mg twice daily, plus standard weekly cetuximab
Study: 21874538
Drug: Pitavastatin 4
Normalized name: PITAVASTATIN 4MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 4 mg
Study: 21812889
Drug: Atorvastatin 20
Normalized name: atorvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 20 or 40 mg
Study: 19624299
Drug: IMRT(inv) (inverse-planned
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMRT(inv) (inverse-planned multi-segment solution)
Study: 11035889
Drug: Pramipexole, 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole, 0.5 mg 3 times per day, with levodopa placebo (n = 151)
Study: 11035889
Drug: Carbidopa/levodopa, 25/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa/levodopa, 25/100 mg 3 times per day, with pramipexole placebo (n = 150)
Study: 2062628
Drug: Acellular pertussis
Normalized name: Acellular pertussis vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acellular pertussis vaccine (ACV) booster at 19 months
Study: 6825123
Drug: Tricyclic nucleoside
Normalized name: TRICYCLIC ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricyclic nucleoside phosphate (iv infusion over 15 minutes once every 3 weeks, doses ranged from 25 to 350 mg/m2)
Study: 31310929
Drug: Augmented Depression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented Depression Therapy (ADepT)
Study: 26077241
Drug: Comparator (progestin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparator (progestin or investigator choice chemotherapy)
Study: 23585665
Drug: canagliflozin 100
Normalized name: canagliflozin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: canagliflozin 100 mg/d for 8 days
Study: 24250305
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment intervention
Study: 22226269
Drug: NovoTwist insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NovoTwist insulin pen needle
Study: 11412156
Drug: Nefopam (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefopam (20 mg.4 h‐1)
Study: 11412156
Drug: Propacetamol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol (2 g.6 h‐1)
Study: 11412156
Drug: Morphine alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine alone (Control)
Study: 11412156
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Morphine alone)
Study: 9524832
Drug: Azithromycin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (1,200 mg once weekly)
Study: 2512804
Drug: Crystalline zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalline zinc insulin (CZI) in each liter of TPN solution
Study: 2512804
Drug: No additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: No additional insulin (control group)
Study: 31590681
Drug: Internet Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet Cognitive Therapy
Study: 27897186
Drug: Massage Therapy
Normalized name: CAMPHOR (SYNTHETIC) 30 g in 1 mL / MENTHOL 40 g in 1 mL TOPICAL OIL [CBDMEDIC MASSAGE THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Massage Therapy (MT) - Swedish massage to upper body
Study: 23884387
Drug: Beetroot bread
Normalized name: Eazi-Breed CIDR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot bread (BB) - 200 g containing 100 g beetroot (1.1 mmol nitrate)
Study: 23884387
Drug: Control white
Normalized name: SODIUM FLUORIDE 1.1 mg in 1 g DENTAL PASTE, DENTIFRICE [Colgate Tartar Control Whitening Crisp Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control white bread (CB) - 200 g (0 g beetroot, 0.01 mmol nitrate)
Study: 21642845
Drug: Group-based multidisciplinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based multidisciplinary rehabilitation program plus oral medication
Study: 25546488
Drug: Oral medication
Normalized name: Oral Medication Syringe 3mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral medication alone
Study: 16490803
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg administered with a high-fat/high-calorie meal
Study: 16490803
Drug: Telbivudine 600
Normalized name: telbivudine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telbivudine 600 mg administered without a high-fat/high-calorie meal (fasting)
Study: 10353617
Drug: Amifostine pretreatment
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine pretreatment (910 mg/m2)
Study: 10353617
Drug: Chemotherapy (cisplatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (cisplatin, adriamycin, cyclophosphamide)
Study: 1968783
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg esmolol IV
Study: 1968783
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg esmolol IV
Study: 1971318
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy (amoxicillin and metronidazole with CBS)
Study: 7395772
Drug: Carnitine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnitine (0.5 g for 8 weeks, then 1.0 g for 6 weeks)
Study: 28361826
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 mg once daily for six months)
Study: 9873217
Drug: Hard water
Normalized name: Hard fat
DrugBank: Hard fat (DB11578)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard water (Ca2+ 255 mg/l)
Study: 9873217
Drug: Soft water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soft water (Ca2+ 22 mg/l, Fiuggi water)
Study: 1848167
Drug: Carbidopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbidopa (100 mg)
Study: 7031872
Drug: 3 daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3 daily doses of 220 mg oral zinc sulfate
Study: 24946626
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment continued for 3 months follow-up.
Study: 24946626
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment before and after treatment comparison.
Study: 24946626
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received regular hemodialysis and conventional medication without moxibustion.
Study: 20643988
Drug: Error-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-free treatment plans in uncomplicated encounters
Study: 20643988
Drug: Error-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-free treatment plans in biomedically complicated encounters
Study: 20643988
Drug: Error-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-free treatment plans in contextually complicated encounters
Study: 20643988
Drug: Error-free treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Error-free treatment plans in combined biomedically and contextually complicated encounters
Study: 15830219
Drug: 0.45 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g/kg alcohol
Study: 10726009
Drug: Aprosulate 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprosulate 0.5 mg/kg body weight
Study: 10726009
Drug: Aprosulate 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprosulate 1.0 mg/kg body weight
Study: 10726009
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (Calciparin 7,500 IU)
Study: 7734259
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 40 mg kg‐1 i.v. pretreatment
Study: 7038839
Drug: Oral prostaglandin
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prostaglandin E2 (PGE2), 0.33 mg three times daily
Study: 7038839
Drug: 15(R)15 Me
Normalized name: LIMOSILACTOBACILLUS FERMENTUM ME-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15(R)15 Me PGE2, 40 micrograms three times daily
Study: 7038839
Drug: Indomethacin, 50
Normalized name: Indomethacin, 50 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin, 50 mg three times daily
Study: 26946614
Drug: Acupuncture-movement therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-movement therapy (AM)
Study: 26946614
Drug: Sham acupuncture-movement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture-movement therapy (SAM)
Study: 28778550
Drug: Carbohydrate‐electrolyte solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte solution (CE)
Study: 7989943
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy for patients with measurable disease
Study: 7989943
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy for patients with assessable disease
Study: 2692375
Drug: Intraperitoneal cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal cisplatin therapy
Study: 25156082
Drug: Controlled drugs
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled drugs or vehicle
Study: 22490808
Drug: Step-up infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Step-up infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Study: 22490808
Drug: Top-down infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Top-down infliximab therapy (5 mg/kg body weight, induction regimen of 3 doses at week 0, 2, and 6, maintenance every 8 weeks starting at week 14)
Study: 22490808
Drug: Step-up infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Step-up infliximab therapy
Study: 22490808
Drug: Top-down infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Top-down infliximab therapy
Study: 9133197
Drug: alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 15 mu g/kg
Study: 9133197
Drug: alfentanil 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 30 mu g/kg
Study: 9133197
Drug: suxamethonium 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: suxamethonium 1.0 mg/kg
Study: 9133197
Drug: alfentanil 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 15 mu g/kg and alfentanil 30 mu g/kg
Study: 8213541
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg IS-5-MN
Study: 8213541
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg IS-5-MN
Study: 8213541
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg IS-5-MN
Study: 2890369
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg etretin daily
Study: 2890369
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg etretin daily
Study: 2890369
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etretin daily
Study: 29777950
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU; n=44)
Study: 16514327
Drug: Lidocaine (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (all doses)
Study: 19250161
Drug: LHA formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHA formulation (twice a day)
Study: 16707816
Drug: Placebo (lactose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (lactose tablet) with normal diet for 4 weeks
Study: 7855219
Drug: Control infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control infusions
Study: 28238195
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (5 loading doses every 4 weeks until week 16, then extended to 8 weeks)
Study: 26554774
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (intravenous fluid until oral diets initiated), n = 19
Study: 19562622
Drug: Fasting preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting preparation
Study: 19562622
Drug: Non-fasting preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fasting preparation
Study: 19562622
Drug: Fasting preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting preparation (in male patients)
Study: 17591658
Drug: S-ketamine (moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (moderate and high doses)
Study: 17591658
Drug: N,N-dimethyltryptamine (DMT)
DrugBank: Dimethyltryptamine (DB01488)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N,N-dimethyltryptamine (DMT) (moderate and high doses)
Study: 9444446
Drug: mibefradil 50
Normalized name: mibefradil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: mibefradil 50 mg QD (titrated to 100 mg if needed)
Study: 9444446
Drug: amlodipine 5
Normalized name: amlodipine 5 MG
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5 mg QD (titrated to 10 mg if needed)
Study: 2735335
Drug: sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: sucralfate 1 g four times per day
Study: 2735335
Drug: cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: cimetidine 400 mg twice daily
Study: 4613534
Drug: Quingestanol acetate
Normalized name: quinestradol
DrugBank: Quingestanol acetate (DB14679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quingestanol acetate 800 mcg in Mexico
Study: 4613534
Drug: Quingestanol acetate
Normalized name: quinestradol
DrugBank: Quingestanol acetate (DB14679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quingestanol acetate 750 mcg in Chile and Peru
Study: 28260598
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment (weekly for five consecutive weeks at predefined acupuncture points: CV-3, CV-4, LR-8, SP-6, SP-9)
Study: 24136731
Drug: ARA 290
Normalized name: 2-fluoro ARA-A
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARA 290 (daily subcutaneous administration for 28 days)
Study: 21288841
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (12-week course of clarithromycin and rifabutin)
Study: 19614943
Drug: Basic Lifestyle
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic Lifestyle Programme (BLP) targeting total daily steps
Study: 10867599
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate (BDP) via conventional pressurised metered-dose inhaler (pMDI) with spacer
Study: 10867599
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (DPI and pMDI)
Study: 3531220
Drug: Naloxone (NLX;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (NLX; 0.08 mg/kg BW, iv)
Study: 22537732
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy insomnia intervention
Study: 22537732
Drug: Traditional depression-focused
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional depression-focused treatment
Study: 16171419
Drug: 4-factor solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-factor solution
Study: 12234860
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg daily for 30 days
Study: 2126396
Drug: Short-term continuous
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term continuous treatment with ST and TNL
Study: 2126396
Drug: Long-term continuous
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term continuous treatment with ST
Study: 91889
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg naloxone (intervention)
Study: 25531536
Drug: Voucher-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher-based treatment with motivational counseling (14 days of vouchers for complete smoking abstinence after a 5-day smoking reduction lead-in period)
Study: 25531536
Drug: Voucher-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voucher-based treatment with motivational counseling (vouchers not contingent on abstinence)
Study: 23884486
Drug: Itraconazole 200-mg
Normalized name: itraconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 200-mg tablet QD for 12 weeks
Study: 23884486
Drug: Itraconazole 100-mg
Normalized name: itraconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Itraconazole 100-mg capsules QD for 12 weeks
Study: 19302902
Drug: Cefepime IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime IV at a dose of 1 g q8h
Study: 17403273
Drug: Inulin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inulin (10 g/d) for 21 days
Study: 15509187
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg plus colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with breakfast
Study: 15509187
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg administered with breakfast, followed 4 hours later by colesevelam HCl 3750 mg (6 x 625 mg tablets) administered with lunch
Study: 15509187
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg administered with breakfast
Study: 11813601
Drug: Locoregional immunochemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional immunochemotherapy combined with systemic chemotherapy (Group A)
Study: 11813601
Drug: Systemic immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic immunotherapy combined with systemic chemotherapy (Group B)
Study: 8064995
Drug: IINS (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IINS (Insulin + Amino Acids)
Study: 8064995
Drug: IIINS (Insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: IIINS (Insulin + Higher Nitrogen Load)
Study: 20882421
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (20 mg of elemental zinc per day for 5 days)
Study: 15963089
Drug: Glyceryl trinitrate
Normalized name: Glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glyceryl trinitrate (GTN) 0.5 mg sublingual
Study: 15963089
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg daily for 4 days